Wall Street also recommends these companies
Growth-oriented investors may be interested in the following small-cap stocks, as they represent businesses whose trailing 12-month earnings per share improved significantly on a year-over-year basis.
Sell-side analysts on Wall Street are also forecasting that these stocks will continue to improve their earnings over the coming years.
Sykes Enterprises Inc
The first stock to consider is Sykes Enterprises Inc (NASDAQ:SYKE), a Tampa, Florida-based international provider of business process outsourcing services with a market capitalization of $1.65 billion.
Sykes Enterprises’ trailing 12-month pro forma earnings were $2.72 per share as of the last quarter of 2020, a nearly 30% increase from trailing 12-month pro forma earnings of $2.11 per share as of the same quarter in 2019.
Wall Street sell-side analysts predict that on a year over year basis, Sykes Enterprises’ EPS will increase by 9.6% to $2.96 in full-year 2021 and by 15.9% to $3.43 in full-year 2022. Over the next five years, the EPS is expected to increase by 10% on average per annum.
The share price ($41.74 as of March 1) has risen by nearly 36.27% over the past year for a 52-week range of $22.12 to $43.68.
On Wall Street, the stock has a median buy recommendation rating with an average target price of $52 per share.
The second stock to consider is Qutoutiao Inc (NASDAQ:QTT), a Shanghai, China-based provider of light entertainment content through mobile platforms with a market capitalization of $1.02 billion.
Qutoutiao Inc saw its trailing 12-month pro forma net loss, which stood at 63 cents per share as of the third quarter of 2020, improving significantly from the net loss of $1.33 per share reported in the same quarter of 2019.
Sell-side analysts predict that Qutoutiao’s bottom line result will continue to improve to a net profit of 5 cents per common share in full-year 2021, which would represent a 113.50% increase from a net loss of 37 cents per share projected for full-year 2020.
The share price ($3.84 as of March 1) has fallen by 26.84% over the past year, determining a 52-week range of $1.53 to $5.64.
On Wall Street, the stock has a median buy recommendation rating.
The third stock to consider is Cerus Corp (NASDAQ:CERS), a Concord, California-based developer of blood systems for platelets and plasma. It markets its biomedical and surgical products under the INTERCEPT brand. The stock has a market capitalization of $1.10 billion.
Cerus saw its trailing 12-month pro forma net loss, which was 36 cents per diluted share as of the fourth quarter of 2020, improving from the net loss of 52 cents per share reported in the prior-year quarter.
Wall Street sell-side analysts predict that the net loss will decrease 8.10% to 34 cents per share in full-year 2021 and by 14.7% to 29 cents per share in full-year 2022.
The share price ($6.52 as of March 1) has risen by 27.72% over the past year for a 52-week range of $2.71 to $8.87.
On Wall Street, the stock has a median buy recommendation rating with an average target price of about $9.10 per share.
Disclosure: I have no positions in any securities mentioned.
Read more here:
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
About the author:
I am a contributor at GuruFocus. I primarily write about how to pick potential value stocks. Gold, silver and precious metals mining industries is also my cup of tea. My articles have also been widely linked by popular sites, including MarketWatch, Financial Times, 24hGold, Investopedia, Financial.org, CNBS, MSN Money, Zachs, Reuters and others. I hold a Master\\\’s Degree in Business Administration from Università degli Studi di Bari (Italy), Aldo Moro. I am based in The Netherlands.
You can follow me on Twitter at https://twitter.com/AAbaterusso
Please leave your comment:
More GuruFocus Links
Your selection and notes will be stored in your portfolio.